SLC5A2 and obesity disorder: Adingupu et al. [16] demonstrated that SGLT2 inhibitor treatment improved coronary flow velocity reserve based on isoflurane-induced hyperemia and ultrasound imaging in an ob/ob-/- mouse model of obesity.